Respiratory Complex III Inhibition via Phe90 Regulatory Switch
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective inhibitors for the mitochondrial electron transport chain, particularly respiratory complex III, which is crucial for inducing ROS production in cancer cells while sparing normal cells, to treat cancer effectively.
Innovation Solution
Development of novel ligand compounds that bind to a newly identified Non-Q binding site on respiratory complex III, inhibiting its function by switching the internal switch Phe90 residue to an 'off' conformation, thereby reducing electron transfer and increasing ROS production selectively in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional inhibitors targeting Qo or Qi sites are used, then respiratory complex III inhibition is achieved, but selectivity between cancer cells and normal cells cannot be obtained
Solution Approach 1:
The invention segments the respiratory complex III into distinct functional regions by identifying and targeting a specific regulatory switch (Phe90 residue) separate from the conventional Qo and Qi binding sites. This segmentation allows for selective inhibition of the regulatory mechanism without affecting the natural substrate binding regions, thereby achieving cancer cell selectivity while maintaining the natural electron transport function in normal cells.
Solution Approach 2:
The invention applies local quality by designing ligands that specifically interact with the Phe90 residue and its surrounding microenvironment in the NQ site. The local structural characteristics and electronic properties of this regulatory region are exploited to create selective inhibition, where the ligand's specific chemical features match the unique local properties of the Phe90 switch region, enabling selective cancer cell targeting.
2Reliability
If ligands bind to Qo or Qi sites, then respiratory complex III inhibition is achieved, but natural ligand binding is interfered with
Solution Approach 1:
The invention extracts the regulatory control function from the natural substrate binding pathway by targeting the Phe90 residue separately from the Qo and Qi sites. This extraction allows inhibition of respiratory complex III through a parallel regulatory mechanism that does not interfere with the natural binding and oxidation of ubiquinol at the Qo site or ubiquinone reduction at the Qi site.
Solution Approach 2:
The Phe90 residue acts as an intermediary that mediates the inhibition effect without directly blocking the natural ligand binding sites. The ligand binds to the NQ site and induces conformational changes in Phe90, which then indirectly affects the electron transfer between heme groups, thereby inhibiting respiratory complex III function without physically obstructing the Qo or Qi sites for natural substrate binding.
3Speed
If rapid ROS production is induced in cancer cells, then apoptosis is triggered, but antioxidant up-regulation can adapt and reduce effectiveness
Solution Approach 1:
The invention implements preliminary action by designing ligands that pre-position themselves at the NQ site to induce an 'off' conformation of the Phe90 residue before substrate binding occurs. This preliminary conformational change blocks the electron transfer pathway in advance, ensuring that when ubiquinol binds at the Qo site, electrons cannot be transferred to heme bL and subsequently to heme bH, thereby preventing ROS production at the source and triggering rapid apoptosis before antioxidant defenses can activate.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel ligands effectively inhibit respiratory complex III, enhancing ROS production specifically in cancer cells, offering a potential therapeutic approach for cancer treatment by designing 'mitocan' drugs that target this mechanism.
Implementation Method 1
contacting the cell with a compound, thereby binding the compound to respiratory complex III
Implementation Method 2
switching the internal switch Phe90 residue to an off conformation
Implementation Method 3
electron transfer between heme bL and heme bH of the low potential redox chain
Implementation Method 4
enhancing ROS production specifically in cancer cells
Data Source
AI summary
The present invention provides methods for inhibiting respiratory complex III in a cell. The present invention also provides methods for treating cancer in a subject.